Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093.

Considerations for controlling invasive meningococcal disease in high income countries.

Author information

1
Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.

Abstract

The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income countries. We present an argument for adequate post-marketing surveillance to monitor epidemiological shifts and to provide a context for the safety and reactogenicity of serogroup B vaccines, including the newer recombinant vaccines. We also offer a series of recommendations to address possible concerns about vaccine safety.

PMID:
22607900
DOI:
10.1016/j.vaccine.2011.12.093
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center